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Chapter	  2	  
	  
Probing	   individual	   subunits	   of	   homooligomeric	  
proteins:	   Generating	   functional	   heterooligomers	   of	   a	  
homooligomeric	  membrane	  protein	  in	  vivo	  
	  Jan	  P.	  Birkner,	  Bert	  Poolman	  &	  Armağan	  Koçer	  
	  
Homooligomeric	  proteins	  are	  abundant	  in	  nature,	  but	  understanding	  
their	  functioning	  at	  the	  molecular	  level	  is	  complicated	  by	  the	  difficulty	  
to	  probe	  individual	  subunits.	  Here,	  we	  describe	  a	  method	  to	  generate	  
and	   purify	   distinct,	   functional	   heteropentamers	   of	   a	   protein	   that	   is	  
naturally	  homopentameric,	  i.e.	  the	  ‘mechanosensitive	  channel	  of	  large	  
conductance’	   (MscL).	   The	   building	   blocks	   for	   heterooligomerization	  
are	   encoded	   by	   a	   wildtype	   (WT-­‐StrepII)	   and	   a	   point	   mutated	  mscL	  
gene	  (G22C-­‐His).	  Upon	  coexpression	  from	  a	  newly	  designed	  duet	  gene	  
expression	   system,	   p2BAD,	   these	   building	   blocks	   form	   subunit	  
resolved,	   addressable	   heteropentamers	   in	   vivo.	   The	   assembled	  
heteropentamers	   of	   MscL	   have	   a	   varying	   number	   of	   wildtype	   and	  
addressable	   G22C	   monomers,	   i.e.	   from	   none	   to	   five,	   and	   can	   be	  
separated	   on	   the	   basis	   of	   their	   subunit	   composition.	   Thereby,	   our	  
method	  provides	  a	  straightforward	  tool	  to	  access	  individual	  subunits	  
of	   homooligomeric	   proteins	   with	   single	   residue	   resolution,	   which	  
enables	  obtaining	  new	  insight	  into	  their	  structure	  and	  function.	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Introduction	  
	  The	  majority	  of	  proteins	  in	  cells	  are	  oligomers	  with	  two	  or	  more	  subunits	  (46).	  The	  simple	  and	  finite	  architecture	  of	  proteins	  with	  identical	  subunits,	  
i.e.	  homooligomers,	   has	   a	   positive	   effect	   on	   protein	   stability,	   allows	   tight	  control	   of	   oligomer	   assembly	   and	   is	   favored	   by	   nature	   (46,	   70,	   98).	   For	  example	   in	   Escherichia	   coli	   (E.	   coli),	   the	   percentage	   of	   homo-­‐	   and	  heterooligomers	  is	  79	  and	  21,	  respectively	  (46).	  Homooligomeric	  proteins	  conduct	  important	  processes	  such	  as	  sugar	  hydrolysis	  (e.g.	  β-­‐	  galactosidase	  (65)),	   cellular	   signaling	   (e.g.	   sensor	   kinases	   in	   two-­‐component	   regulatory	  systems	   (96)),	   or	   membrane	   transport	   (e.g.	   channel	   proteins	   (129)).	  Although	   they	  are	  made	  up	  of	   identical	   subunits,	   it	   is	  hard	   to	   study	   these	  proteins.	   Their	   analyses	   by	  mutagenesis	   and	   site-­‐specific	   labeling	   studies	  are	   complicated	   by	   the	   multiplication	   of	   the	   modifications.	   Even	   though	  this	  can	  be	  used	  as	  an	  advantage	  in	  some	  cases,	  most	  of	  the	  time	  multiple	  signals	   complicate	   the	   interpretation	   of	   data.	   Signal	   averaging,	   loss	   of	  information	  from	  symmetrical	  or	  asymmetrical	  arrangements,	  or	  cross-­‐talk	  of	  reporter-­‐labels	  are	  examples	  of	  difficulties	  one	  may	  face.	  So	  far,	  different	  approaches	  have	  been	  used	  to	  resolve	  homooligomers	  to	  the	  subunit	  level,	  such	   as	   tandem	   gene	   expression	   (42),	   dissociation	   and	   re-­‐association	   of	  homooligomers	   (25),	   or	   in	   vitro	  expression	   of	   the	   protein	   (114).	   Each	   of	  these	   methods	   has	   its	   own	   merits	   but	   a	   general	   method	   to	   efficiently	  generate	   and	   separate	   the	   oligomeric	   assemblies	   is	   lacking.	   Here,	   we	  describe	   a	   new	   method	   that	   converts	   homooligomeric	   proteins	   into	  individually	  addressable	  heterooligomers	  in	  vivo	  to	  enable	  their	  separation	  
in	  vitro.	  The	  procedure	  comprises	  duet	  gene	  expression	  using	  a	  specifically	  designed	   plasmid	   (p2BAD),	   in	   vivo	   heterooligomerization	   of	   individual	  subunits,	   and	  a	   straight-­‐forward	   three-­‐step	  protein	  purification.	  The	  duet	  gene	   expression	   system	  p2BAD	   allows	   hosting	   of	   two	   genes	   on	   the	   same	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plasmid,	   each	   under	   the	   control	   of	   its	   own	  promoter.	   Since	   a	   single	   gene	  encodes	   homooligomeric	   proteins,	   we	   generated	   heterooligomers	   by	  providing	  two	  slightly	  different	  gene	  variants	  within	  the	  same	  host-­‐cell	   in	  two	   independent	   multiple	   cloning	   sites	   (MCS)	   of	   the	   duet	   expression	  system.	   One	  MCS	   carried	   the	  wildtype	   gene	   and	   the	   other	  MCS	   carried	   a	  mutated	   version	   of	   the	   same	   gene.	   The	   mutation	   can	   be	   of	   any	   nature	  including	  a	  point	  mutation	  that	  codes	  for	  a	  desired	  amino	  acid,	  which	  can	  be	  used	   later	   for	   specific	   labeling	   and/or	  probing	  of	   the	  heterooligomers.	  Furthermore,	  one	  of	  the	  genes	  was	  tagged	  with	  6-­‐Histidine	  and	  the	  second	  gene	   was	   tagged	   with	   StrepII-­‐tag	   at	   the	   end.	   Once	   E.	   coli	   cells	   were	  transformed	  with	  this	  plasmid,	  both	  genes	  were	  expressed	  and	  the	  cellular	  machinery	   formed	   the	  possible	  combinations	  of	   individual	  gene	  products.	  After	   the	   heterooligomers	   were	   formed	   in	   vivo,	   the	   individual	   oligomers	  were	   isolated	   on	   the	   basis	   of	   their	   biochemical	   and	   electrochemical	  properties,	   which	   arise	   from	   the	   varying	   number	   and	   type	   of	   the	   tags	   in	  each	  heteropentamer.	  Here,	   we	   applied	   our	   method	   to	   a	   homopentameric	   protein,	   the	  mechanosensitive	  channel	  of	   large	  conductance	  (MscL),	  from	  E.	  coli	  (127).	  As	  described	  more	  detailed	   in	  Chapter	  1	  of	   this	  thesis,	   the	  current	  model	  for	   gating	   of	   MscL	   describes	   an	   iris-­‐like	   movement	   of	   the	   subunits	   (13).	  However,	  so	  far	  our	  knowledge	  on	  the	  gating	  mechanism	  of	  MscL	  is	  limited	  to	   the	   structural	   information	   from	  snapshots	  of	   the	   closed	  and	   fully	  open	  channel,	   while	   due	   to	   its	   homopentameric	   nature	   little	   is	   known	   of	   the	  initial	   and	   intermediate	   states	   (137).	   Spectroscopic	   techniques	   could	   be	  helpful	   to	   resolve	   the	   gating	   mechanism	   in	   more	   detail,	   provided	   the	  individual	   subunits	   can	   be	   triggered	   and	   probed.	   Resolving	   MscL	  homooligomers	   by	   converting	   them	   into	   heterooligomers,	   in	   which	  subunits	  can	  be	  addressed	  individually,	  would	  enable	  such	  an	  approach.	  	  In	  this	  study,	  we	  generated	  functional	  heteropentamers	  of	  MscL	  that	  were	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composed	   of	   its	   wildtype	   and	   single	   point	   mutant,	   G22C.	   Duet	   gene	  expression	   in	  E.	   coli	   generated	   all	   the	   expected	   heteropentamers	   and	  we	  could	  separate	  and	  identify	  them	  individually.	  In	  patch	  clamp	  experiments	  we	   showed	   that	   all	   heteropentamers	   retained	   their	   activity.	   Our	   method	  provides	   a	   tool	   to	   go	   beyond	   the	   technical	   limitations	   of	   working	   with	  homooligomeric	   proteins,	   in	   general,	   and	   makes	   it	   possible	   to	   address	  individual	  subunits	  within	  a	  functional	  complex.	  	  	  
Results	  
	  
MscL	  can	  be	  converted	  into	  heteropentamers	  in	  vivo	  To	   obtain	   heteropentamers	   of	  MscL,	   we	   first	   designed	   a	   duet	   expression	  system,	  p2BAD	  (Figure	  1	  A,	  B).	  Although	  the	  principle	  of	  duet	  expression	  in	   E.	   coli	   is	   not	   new	   (132),	   our	   system	   overcomes	   the	   restriction	   of	   the	  requirement	   for	   a	   specific	   host,	   hence	   it	   is	   compatible	   with	   any	   E.	   coli	  strain.	  This	  feature	  allows	  the	  unlimited	  access	  and	  use	  of	  the	  broad	  range	  of	  existing	  knock-­‐out	  or	  specific	  knock-­‐in	  strains.	  The	  plasmid	  p2BAD	  was	  derived	   from	   the	   backbone	   of	   pBAD24	  (49)	   by	   doubling	   the	   promoter	   to	  terminator	   region	   of	   the	   parental	   plasmid	   and	   introducing	   two	  complementary	   multiple	   cloning	   sites	   (for	   detailed	   information	   on	   the	  plasmid	  construction	  see	  methods	  section).	  The	  characteristics	  (49)	  of	  the	  parental	  pBAD	  system	  have	  been	  retained	  and	  are	  complemented	  with	  the	  ability	   to	   host	   two	   genes,	   each	   controlled	   by	   its	   own	   araBAD	   promoter	  (Figure	  1	  B).	  For	  heterooligomerization	  of	  MscL,	  we	  cloned	  two	  mscl	  genes	  [encoding	  for	  the	   wildtype	   MscL	   with	   StrepII-­‐tag	   (WT)	   and	   the	   single	   cysteine	   mutant	  with	   His-­‐tag	   (G22C)]	   in	   p2BAD.	   Coexpression	   of	   these	   genes	   in	   E.	   coli	  PB104	  (21)	  produced	  nearly	  equal	  quantities	  of	  each	  monomer.	  Assuming	  that	  both	  genes	  were	  expressed	  equally	  and	  the	  resulting	  MscL	  monomers	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Figure	   1	   |	   Strategy	   to	   obtain	   well-­‐resolved	   heterooligomeric	   protein	   complexes.	  A	  Features	   of	   the	   duet	   expression	   plasmid	   p2BAD.	  B	   Organization	   of	   regulatory	   sequences	  controlling	   the	   duet	   expression	   of	   the	   individual	   genes.	   C	   Schematic	   representation	   of	  possible	  permutations	  and	  calculated	  occurrences	  (%)	  of	  individual	  pentamers.	  D	  Isolation	  of	   heteropentamers	   by	   Ni-­‐NTA	   agarose	   and	   StrepTactin	   Superflow	   affinity	  chromatographies.	  E	  Separation	  of	  heteropentamers	  by	  means	  of	  differences	  in	  their	  surface	  pI	  F	  Exemplary	  chromatofocusing	  profile	  of	  MscL	  heteropentamers.	  
	  assembled	  randomly	  one	  can	  calculate	  the	  expected	  permutations	  and	  the	  probability	  of	  their	  occurrences	  (Figure	  1	  C).	  	  
Individual	   heteropentamers	   can	   be	   resolved	   by	   two-­‐step	   affinity	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pentamers	   with	   at	   least	   one	   His-­‐tag	   remained	   bound	   to	   the	   column,	  whereas,	   most	   contaminants	   and	   homopentameric	   WT-­‐StrepII5	   were	  eliminated	  in	  the	  flow-­‐through	  and	  washing	  steps.	  Subsequently,	  the	  eluate	  was	  applied	  to	  a	  StrepTactin	  column,	  for	  removing	  homopentameric	  G22C-­‐His5	   and	   obtaining	   the	   mixture	   of	   heteropentamers.	   Next,	   individual	  heteropentamers	  in	  the	  mixture,	  namely	  WT4G22C1,	  WT3G22C2,	  WT2G22C3,	  and	   WT1G22C4,	   were	   separated	   from	   each	   other	   on	   the	   basis	   of	   their	  isoelectric	  points	  (pI)	  (Figure	  1	  E).	  	  Although	   the	   His-­‐	   and	   the	   StrepII-­‐tags	   are	   only	   6	   and	   7,	   respectively,	  residues	   long,	   they	   differ	   in	   their	   electrochemical	   properties	   and	   thus	  influence	   the	   pI	   values	   of	   the	   individual	   complexes.	   Therefore,	  chromatofocusing	  (121,	  122),	  that	   is	   isoelectric	  focusing	  of	  proteins	  on	  an	  ion	  exchange	  column,	  was	  chosen	  to	  separate	  the	  heteropentamers	  (Figure	  
1	  E).	  The	  implementation	  of	  this	  technique	  is	  simple	  and	  requires,	  next	  to	  the	   ion-­‐exchange	   column,	   just	   two	   buffers.	   The	   first	   one	   is	   used	   to	  equilibrate	  the	  column	  and	  sets	  the	  upper	  pH	  limit,	  and	  the	  second	  one,	  a	  Polybuffer,	  is	  used	  for	  elution	  and	  defines	  the	  lower	  pH	  limit.	  Elution	  with	  the	  amphoteric	  Polybuffer	  facilitates	  a	  self-­‐generating	  pH	  gradient.	  The	  pH	  values	   of	   the	   chosen	   buffers	   ideally	   frame	   the	   isoelectric	   point	   of	   the	  protein(s)	  of	   interest,	  e.g.	  pH	  9	  and	  pH	  6	  when	  the	  protein	  has	  a	  pI	  of	  7.5.	  For	  more	   information	  on	  the	  development	  of	  chromatofocusing	  protocols,	  the	   manufacturers	   guideline	   for	   chromatofocusing	   provides	   a	   valuable	  resource	   (Ion	   exchange	   chromatography	   and	   chromatofocusing	   –	  principles	  and	  methods,	  GE	  Healthcare).	  As	   a	   starting	   point	   and	   to	   estimate	   the	   pH	   range	   for	   the	   separation,	   the	  theoretical	  pI	  of	  the	  homo-­‐	  and	  heteropentamers	  were	  determined	  using	  an	  online-­‐based	   bioinformatics	   tool	   (http://web.expasy.org/protparam/)	  (43).	   Heteropentamers	   of	   MscL	   have	   calculated	   pIs	   ranging	   from	   7.3	  (WT4G22C1)	   to	   7.5	   (WT1G22C4).	   After	   empirical	   optimization	   of	   the	   pH	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range,	   a	   pH	   gradient	   from	   8	   to	   5	   yielded	   optimal	   separation	   of	   both	  homopentamers.	  One	  ml	  of	  0.6	  mg/ml	  heteropentamer	  mixture	  obtained	   from	  Strep-­‐tactin	  column	   was	   chromatofocused	   on	   a	   Mono	   P	   5/200	   GL	   column	   with	  Polybuffer.	   The	   chromatogram	   (Figure	   1	   F)	   with	   four	   separated	   peaks	  confirmed	  the	  random	  assembly	  of	  individual	  subunits	  as	  predicted	  before	  (Figure	   1	   C).	   The	  mixture	  was	   resolved	   into	   four	   characteristic	   fractions	  with	  isoelectric	  points	  (pI)	  (Mean	  ±	  SD)	  of	  7.33	  ±	  0.02,	  7.17	  ±	  0.02,	  6.94	  ±	  0.02,	  and	  6.65	  ±	  0.01.	  From	  0.6	  mg	  of	  starting	  heteropentamer	  mixture	  (in	  1	   ml	   volume),	   we	   obtained	   500	   μL	   of	   each	   of	   the	   heteropentameric	  assemblies	   at	   a	   final	   protein	   concentration	   between	   0.15	  mg/ml	   and	   0.3	  mg/ml,	  corresponding	  to	  an	  overall	  recovery	  of	  about	  75	  %	  of	   the	   loaded	  protein.	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The	   type	   of	   heteropentamer	   in	   individual	   fractions	   was	   determined	   by	  quantification	   of	   their	   G22C-­‐	   and	   WT-­‐	   subunits.	   For	   that,	   site-­‐directed	  PEGylation	   of	   cysteine	   residues	   in	   each	   fraction	   with	  Methoxypoly(ethyleneglycol)5000	   Amidopropionyl	   Methanethiosulfonate	  (MTS-­‐PEG5000)	  was	  followed	  by	  separation	  of	  the	  subunits	  on	  SDS-­‐PAGE.	  For	  high-­‐sensitivity	  protein	  detection	  all	  samples	  were	  additionally	  labeled	  with	  an	  excess	  of	  lysine-­‐specific	  Cy5	  prior	  to	  gel	  loading.	  The	  relative	  band	  intensities	  (Figure	  2	  A),	  as	  calibrated	  with	  defined	  MscL	  standards	  (Figure	  2	  B),	  indicated	  that	  each	  fraction	  indeed	  contained	  one	  of	   the	   distinct	   heteropentamers	   and	   the	   elution	   order	  was	  WT1G22C4	   (pI	  7.33	  ±	  0.02),	  WT2G22C3	   (pI	   7.17	  ±	  0.02),	  WT3G22C2	   (pI	   6.94	  ±	  0.02),	   and	  WT4G22C1	  (pI	  6.65	  ±	  0.01).	  	  
Heteropentamers	  of	  MscL	  retain	  tension	  sensitivity	  Since	   the	   C-­‐terminal	   fusion	   of	   a	   His-­‐tag	   to	   MscL	   is	   well	   established	   and	  characterized,	   we	   first	   showed	   that	   also	   the	   StrepII-­‐tag	   at	   the	   end	   of	   the	  homopentameric	  WT	  has	  no	  influence	  on	  the	  functioning	  of	  the	  protein	  in	  its	   natural	   environment.	   Therefore,	   we	   produced	   spheroplasts	   of	   E.	   coli	  cells	   for	   patch	   clamp	   electrophysiology.	   Patch	   clamp	   allows	   evoking	  membrane	   tension	   and	   thereby	   triggering	   MscL	   in	   a	   native	   way.	   We	  determined	   the	   relative	   MscL/MscS	   threshold	   for	   WT-­‐StrepII	   in	  spheroplasts	  and	  compared	  it	  to	  WT	  MscL.	  The	  relative	  threshold	  to	  MscS	  was	  1.45	  ±	  0.07	  (n=2)	  (Mean	  ±	  SEM)	  for	  WT	  and	  1.50	  ±	  0.16	  (n=3)	  for	  WT-­‐StrepII.	  These	  values	  are	  comparable	  to	  published	  data,	  where	  the	  relative	  threshold	   at	   similar	   experimental	   conditions	  was	   1.39	   ±	   0.04	   (n=6)	   (21).	  This	  experiment	  proved	  the	  tag	  not	  to	  influence	  MscLs’	  tension	  sensitivity.	  In	   order	   to	   test	   the	   individual	   heteropentameric	   complexes	   of	   MscL	   for	  their	  functionality,	  we	  reconstituted	  each	  variant	  into	  synthetic	  liposomes.	  The	  proteoliposomes	  were	  subsequently	  used	  to	  produce	  giant-­‐unilamellar	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vesicles	   (GUV).	   We	   compared	   the	   activity	   of	   the	   reconstituted	  heteropentamers	   of	   MscL	   to	   the	   wildtype	   homopentamer.	   Figure	   3	  indicates	   that	   all	   heteropentamers	   retained	   tension	   sensitivity	   with	  wildtype-­‐like	  open	  channel	  conductance.	  	  
	  
Figure	   3	   |	   Heteropentamers	   of	  MscL	   remain	   tension-­‐sensitivity	   and	   show	  wildtype-­‐
like	   conductance.	   Representative	   single	   channel	   current	   traces	  were	   recorded	   at	   20	  mV	  and	  constant	  pressure	  (~100	  mmHg).	  
	  A	   more	   detailed	   analysis	   of	   the	   heteromeric	   channels	   is	   presented	   in	  
Chapter	   4	   and	   5,	  where	  we	   further	   investigate	   the	   role	  of	   the	   individual	  subunits	  in	  channel	  gating	  using	  sulphydryl-­‐specific	  reagents.	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Discussion	  	  To	   address	   individual	   subunits	   of	   a	   homopentameric	   protein,	   a	   new	  method	   was	   developed	   on	   the	   basis	   of	   a	   duet	   gene	   expression	   system,	  p2BAD.	  Our	  strategy	  was	  to	  produce	  MscL	  protein	  from	  two	  individual	  mscl	  genes.	   The	   genes	   were	   identical	   except	   that	   one	   of	   them	   had	   a	   point	  mutation	  at	  a	  desired	  codon	  in	  order	  to	  generate	  a	  specific	  labeling	  position	  on	   the	   resulting	   MscL	   monomer,	   and	   each	   of	   the	   genes	   code	   for	   a	   MscL	  variant	  with	  a	  different	  affinity	  tag	  for	  purification	  and	  immune-­‐detection.	  We	  show	  that	  the	  unbiased	  expression	  of	  these	  genes	  from	  p2BAD	  and	  the	  stochastic	   assembly	   of	   subunits	   yielded	   a	   library	   of	   both	   homo-­‐	   and	  heteropentameric	  oligomers.	  Previously,	  up	  to	  six	  mscl	  genes	  were	  fused	  in	  tandem	   in	   order	   to	   modify	   single	   amino	   acids	   in	   MscL	   by	   genetically	  connecting	   the	   N-­‐terminus	   of	   one	   subunit	   to	   the	   C-­‐terminus	   of	   the	   next	  subunit	   (42).	   The	   expression	   of	   these	   constructs	   generated	   functional	  channels	   and	   the	   pentameric	   tandem	   had	   WT-­‐like	   properties,	   but	   the	  proteins	   were	   less	   stable	   upon	   detergent	   extraction	   and	   purification.	   In	  retrospect	   the	   linkers	   between	   the	   subunits	  may	   have	   been	   too	   short.	   In	  our	   strategy,	   the	   combination	   of	   p2BAD	   duet	   expression	   and	   the	   in	   vivo	  assembly	  and	  oligomerization	  overcomes	  these	  challenges.	  	  In	   our	   duet	   expression	   system,	   the	   genes	   ligated	   in	   each	   of	   the	   multiple	  cloning	  sites	  were	  fused	  with	  a	  different	  affinity	  tag.	  The	  difference	   in	  the	  number	  of	  individual	  tags	  within	  each	  heteropentamer	  made	  it	  possible	  to	  isolate	   heteropentamers	   in	   a	   straightforward	   three-­‐step	   purification	  procedure.	   The	   non-­‐denaturing	   conditions	   during	   this	   procedure	   provide	  highly	   efficient	   complex	   recovery	   by	   preventing	   the	   loss	   of	   protein-­‐complexes	  by	  dissociation,	  similar	  to	  what	  has	  been	  reported	  for	  the	  very	  stable	  potassium	  channel	  KcsA	  (114).	  In	   this	   study,	   we	   could	   modify	   individual	   subunits	   of	   a	   naturally	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p2BAD	  construction	  The	   plasmid	   p2BAD	  was	   derived	   from	   the	   backbone	   of	   pBAD24	   (49)	   by	  doubling	   the	   promoter	   to	   terminator	   region	   of	   the	   parental	   plasmid	   and	  introducing	   two	   multiple	   cloning	   sites.	   Hence,	   the	   characteristics	   of	   the	  parental	  pBAD	  system	  have	  been	  retained	  and	  are	  complemented	  with	  the	  ability	   to	   host	   two	   genes	   in	   tandem,	   each	   controlled	   by	   its	   own	   araBAD	  promoter	   (Figure	   1	   b).	   p2BAD	  was	   constructed	  using	   traditional	   cloning	  methods.	  The	  promoter,	  transcription	  terminator	  and	  spacer	  regions	  were	  generated	   by	   PCR	   using	   pBAD-­‐myc-­‐his	   B	   (commercial	   variant	   pBAD24,	  Invitrogen)	   as	   template.	   The	   original	  MCS	  was	   expanded	   and	   nucleotides	  encoding	   for	   a	   c-­‐myc	  epitope	   and	  His-­‐tag	  were	   removed.	   Doubling	   of	   the	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promoter	   to	   terminator	   region	   was	   achieved	   by	   insertion	   of	   the	  corresponding	   DNA	   elements	   into	   the	   parental	   pBAD-­‐myc-­‐his	   B	   plasmid,	  resulting	  in	  the	  following	  construction:	  	  5’	  -­‐	  MCS1(partial)	  –Spacer	  -­‐	  Transcription	  Terminator	  –	  Promoter	  –	  Spacer	  –	  RBS	  –	  Spacer	  –	  MCS2	  -­‐	  Spacer(partial)	  –	  3’	  	  The	  insert	  resulted	  in	  two	  nearly	  identical	  promoter-­‐to-­‐terminator	  regions.	  However,	   the	  MCS,	   the	   restriction	   recognition	   sequences,	   and	   the	   spacer	  between	   the	  ribosomal	  binding	  site	   (RBS)	  and	   the	  designated	  start-­‐codon	  were	   different.	   The	   resulting	   p2BAD	   enables	   hosting	   of	   two	   genes,	   each	  being	  expressed	  from	  its	  own	  araBAD	  promoter.	  	  	  In	   detail	   the	   plasmid	   was	   constructed	   as	   follows	   (for	   primer	   details	   see	  Table	  1):	  	  (1) Digest	  pBAD-­‐myc-­‐his	  B	   (Invitrogen,	  4092	  bp)	  with	  NcoI	   and	  HindIII	  leading	  to	  a	  fragment	  of	  4044	  bp	  (Fragment	  1)	  (2) Anneal	  the	  oligonucleotides	  resINS1.fw	  and	  resINS1.rev	  (resINS1)	  to	  expand	   the	   existing	   multiple-­‐cloning	   site	   by	   the	   recognition	  sequences	  for	  PstI	  and	  SpeI	  (3) Ligate	  Fragment	  1	  and	  resINS1	  leading	  to	  Product1	  (4062	  bp)	  (4) Remove	   the	  nucleotides	   specifying	   the	   c-­‐myc	  epitope	  and	  6xHis-­‐tag	  by	  HindIII	  and	  PmeI	  digestion	  of	  Product1,	  which	  leads	  to	  Fragment2	  (3983	  bp)	  (5) Anneal	  the	  oligonucleotides	  resINS2.fw	  and	  resINS2.rev	  (resINS2)	  to	  create	  the	  recognition	  sequences	  for	  HindIII-­‐BglII-­‐NotI-­‐XhoI-­‐PmeI.	  (6) Ligate	   Fragment	   2	   and	   resINS2	   leading	   to	   Product2	   (4012	   bp).	  Product	  2	  is	  designated	  p1BAD.	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(7) Create	   a	   second	   promoter	   region	   using	   p1BAD	   (Product	   2)	   as	  template	   and	   araBAD2.fw	   and	   araBAD2.rev	   as	   primers	   for	   PCR,	  which	  leads	  to	  the	  product	  araBAD2	  (287	  bp)	  (8) Digest	  plasmid	  p1BAD	  and	  PCR	  product	  araBAD2	  with	  NotI	  and	  XhoI,	  which	  yields	  Fragment3	  and	  Fragment4,	  respectively.	  (9) Ligate	  Fragments	  3	  and	  4,	  which	  results	  in	  Product3	  (4285	  bp).	  (10) Anneal	   the	   oligonucleotides	   INSmcs2.fw	   and	   INSmcs2.rev	   (product	  INSmcs2)	   to	   create	   new	  unique	   restriction	   recognition	   sites	   for	   the	  second	  multiple	  cloning-­‐site	  (MCS2).	  (11) Digest	  Product3	  with	  XhoI,	  which	  yields	  Fragment5	  (4285	  bp).	  (12) Ligate	  Fragment5	  and	  INSmcs2,	  which	  results	  in	  Product4	  (4321	  bp).	  (13) Anneal	   the	   oligonucleotides	   mcsINSTerm.fw	   and	   mcsINSTerm.rev	  (product	  mcsINSTerm)	  to	  expand	  MCS1	  (recognition	  sites:	  BglII-­‐AscI-­‐
ClaI-­‐EagI-­‐SacII-­‐SalI-­‐NotI).	  (14) Digest	  Product	  4	  with	  BglII	  and	  NotI	  (Fragment	  6,	  4314	  bp).	  (15) Ligate	  mcsINSTerm	  and	  Fragment	  6	  (Product	  5,	  4353	  bp).	  (16) Perform	  PCR	  on	  Product	  4	  with	  the	  primers	  rrnB+.fw	  and	  rrnB+.rev	  to	  create	  a	  copy	  of	  the	  transcription	  terminator	  (Product	  rrnB+_PCR,	  266	  bp).	  (17) Digest	   Product	   5	   and	   rrnB+_PCR	   with	   SacII	   and	   NotI,	   leading	   to	  Fragment	  7	  and	  Fragment	  8,	  respectively.	  (18) Ligate	  the	  Fragments	  7	  and	  8,	  which	  yields	  Product	  6	  (4599	  bp).	  (19) Perform	   PCR	   on	   p1BAD,	   using	   araBAD2.fw	   and	   araBAD2.rev2	   as	  primers,	  which	  eliminates	  the	  second	  XhoI	  recognition	  site	  upstream	  of	  MCS2	  (Product	  araBAD2rev2_PCR,	  335bp).	  (20) Digest	   Product	   6	   and	   araBAD2rev2_PCR	  with	  NotI	   and	  KpnI,	   which	  yields	  Fragment	  9	  and	  Fragment	  10,	  respectively.	  (21) Ligate	   Fragments	   9	   and	   10,	   which	   yields	   the	   final	   product	   p2BAD	  (sequence	  confirmed,	  4633	  bp).	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Table	  1	  |	  Primer	  for	  the	  construction	  of	  p2BAD,	  insertion	  of	  the	  mscL	  gene,	  and	  sequencing	  of	  DNA	  inserts	  
Primer	   Sequence	   Size	   Info	  
	  	   [5'	  to	  3']	   [bp]	   	  	  
resINS1.fw	   CATGGCTGCAGACTAGTA 18	   NcoI-­‐PstI-­‐SpeI-­‐HindIII	  
resINS1.rev	   AGCTTACTAGTCTGCAGC 18	   NcoI-­‐PstI-­‐SpeI-­‐HindIII	  
resINS2.fw	   AGCTTAGATCTGCGGCCGCCTCGAGGTTT 29	   HindIII-­‐BglII-­‐NotI-­‐XhoI-­‐PmeI	  
resINS2.rev	   AAACCTCGAGGCGGCCGCAGATCTA 25	   HindIII-­‐BglII-­‐NotI-­‐XhoI-­‐PmeI	  
araBAD2.fw	   ATAAGAATGCGGCCGCAAACCAATTGTCCATATTGC 36	   NotI-­‐araBAD	  
araBAD2.rev	   CCGCTCGAGCAGTAGAGAGTTGCGATAAAAAGCG 34	   XhoI-­‐araBAD	  
INSmcs2.fw	   TCGAGAAGGAGGGTACCTCTAGAGAATTCGAGCTCC 36	   XhoI-­‐RBS-­‐KpnI-­‐XbaI-­‐EcoRI-­‐SacI-­‐XhoI	  
INSmcs2.rev	   TCGAGGAGCTCGAATTCTCTAGAGGTACCCTCCTTC 36	   XhoI-­‐RBS-­‐KpnI-­‐XbaI-­‐EcoRI-­‐SacI-­‐XhoI	  
mcsINSTerm.fw	   GATCTGGCGCGCCATCGATCGGCCGCCGCGGGTCGACGC 39	   BglII-­‐AscI-­‐ClaI-­‐EagI-­‐SacII-­‐SalI-­‐NotI	  
mcsINSTerm.rev	   GGCCGCGTCGACCCGCGGCGGCCGATCGATGGCGCGCCA 39	   BglII-­‐AscI-­‐ClaI-­‐EagI-­‐SacII-­‐SalI-­‐NotI	  
rrnB+.fw	   GCCGCGGGGTCTCCAGCTTGGCTGTTTTGGCGGATGAGAG 40	   SacII-­‐Spacer-­‐rrnB	  transcription	  terminator	  
rrnB+.rev	   ATAAGAATGCGGCCGCAAGGCCCAGTCTTTCGACTGAGCC 40	   NotI-­‐rrnB	  transcription	  terminator	  
araBAD2.rev2	   GGGGTACCCTCCTTTTAATTCCTCCTGTTAGCCC 34	   spacer-­‐RBS-­‐KpnI	  (use	  with	  araBAD2.fw)	  
p1/2BAD.fw	   GGGCATTAAACGAGTATCCCGGC 23	   forward	  sequencing	  inserts	  in	  p1BAD	  or	  MCS1	  of	  p2BAD	  
p1/2BAD.rev	   CCGACAAACAACAGATAAAACGAAAGGCC 29	   reverse	  sequencing	  inserts	  in	  p1BAD	  or	  MCS2	  of	  p2BAD	  
p2BAD.rev	   GGTTTGCGGCCGCAAGGCCC 20	   reverse	  sequencing	  inserts	  in	  MCS1	  of	  p2BAD	  
p2BAD.fw	   GGGCCTTGCGGCCGCAAACC 20	   forward	  sequencing	  inserts	  in	  MCS2	  of	  p2BAD	  
MscL_MCS1_NcoI/RcaI.fw	   ATGCTCATGAGCATTATTAAAGAATTTCGC 30	   RcaI-­‐mscL	  
MscL-­‐His.rev	   GGACTAGTTTAATGATGATGATGATGATGAGAGCGG 36	   SpeI-­‐stop	  codon-­‐6xHis-­‐	  mscL	  
MscL-­‐StrepIIMCS1.rev	   GCTTACTAGTTTATTTTTCGAACTGAGGATGAGACCAAGAG 41	   SpeI-­‐Stop	  codon-­‐StrepII-­‐	  mscL	  
MscL_MCS2.fw	   GGGGTACCATGAGCATTATTAAAGAATTTCGC 32	   KpnI-­‐	  mscL	  
MscL-­‐His.rev2	   CCGCTCGAGTTAATGATGATGATGATGATGAGAGCGG 37	   XhoI-­‐stop	  codon-­‐6xHis-­‐	  mscL	  
MscL-­‐StrepIIMCS2.rev	   CCTCGAGTTATTTTTCGAACTGAGGATGAGACCAAGAG 38	   XhoI-­‐stop	  codon-­‐StrepII-­‐	  mscL	  	  Insertion	   of	   the	   genes	   can	   be	   confirmed	   by	  HaeII	   digestion.	   This	   enzyme	  has	   five	   recognition	   sites	   on	   p2BAD	   and	   creates,	   in	   case	   of	   the	   empty	  plasmid,	  a	  designative	  ladder	  of	  DNA	  fragments	  (1802,	  995,	  848,	  617,	  and	  370	  bp).	  Among	  them,	  two	  fragments	  report	  the	  insertion	  of	  genes	  in	  MCS1	  or	   MCS2,	   respectively.	   An	   increase	   of	   the	   995	   bp	   fragment	   reports	   the	  insertion	   of	   a	   gene	   in	   MCS1,	   increasing	   the	   originally	   617	   bp	   fragment	  reports	   the	   insertion	   of	   a	   gene	   in	  MCS2.	   CAVEAT:	   for	   the	   analysis	   of	   the	  restriction	   profile	   one	   has	   to	   keep	   in	   mind	   the	   possibility	   of	   HaeII	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recognition	  sites	  to	  be	  present	  within	  the	  gene	  of	  interest.	  	  	  
Duet	  expression	  Duet	  expression	  of	  mscL	  was	  carried	  out	   in	  E.	  coli	  PB104	  (21)	  (mscL:CmR;	  Ara+).	  CaCl2-­‐competent	  E.	  coli	  PB104	  cells	  were	  transformed	  with	  p2BAD	  WT-­‐StrepII/G22C-­‐His	   and	   grown	   in	   Luria-­‐Bertani	   (LB)	   medium	   in	   the	  presence	   of	   10	   μg/ml	   choramphenicol	   and	   100	   μg/ml	   ampicillin.	   For	  protein	   expression,	   cells	   were	   grown	   in	   a	   bioreactor	   with	   pH	   (pH	   7.5),	  temperature	  (37	  °C)	  and	  oxygen	  control	  (dissolved	  oxygen	  >70	  %),	  using	  a	  complex	   medium	   of	   12	   g/L	   Bacto-­‐	   Tryptone	   (BD),	   24	   g/L	   Yeast-­‐extract	  (BD),	  potassium-­‐phosphate	  (17	  mM	  KH2PO4	  and	  72	  mM	  K2HPO4),	  pH	  7.5,	  supplemented	   with	   chloramphenicol	   and	   ampicillin.	   We	   determined	   the	  cell	  density	  of	  the	  culture	  medium	  at	  regular	  time	  intervals	  (every	  60	  min),	  by	  measuring	   the	  absorbance	  at	  600	  nm	  (A600).	  At	  early	   log-­‐	  and	  mid	   log-­‐phase	   phase	   of	   growth,	   10	   ml	   of	   40	   %	   (v/v)	   glycerol	   were	   added	   as	  additional	  carbon	  source	  per	  liter	  of	  medium.	  In	  the	  late-­‐logarithmic	  phase	  of	  growth,	  protein	  expression	  was	  induced	  by	  adding	  L-­‐arabinose	  at	  0.1%	  (w/v).	   To	   prevent	   depletion	   of	   the	   carbon	   and	   energy	   source	   during	  protein	   expression,	   another	   10	   ml	   40	   %	   (v/v)	   glycerol	   was	   added	   upon	  induction	  and	  cultivation	  was	  continued	  for	  90-­‐120	  minutes.	  	  
Membrane	  vesicle	  preparation	  Cells	  were	  harvested	  by	  centrifugation	  and	  resuspended	  in	  ice-­‐cold	  25	  mM	  Tris-­‐HCl,	  pH	  8.0,	  to	  a	  final	  A600	  of	  about	  100-­‐150.	  Subsequently,	  DNAse	  (0.5	  mg/ml,	  final	  concentration),	  RNAse	  (0.5	  mg/ml,	  final	  concentration)	  and	  5	  mM	   MgSO4	   were	   added	   and	   cells	   were	   broken	   using	   a	   cell	   disrupter	  (Constant	   Systems	  Type	  TS/40)	   at	   1.7	   kbar	   and	  5	   °C.	   Cellular	   debris	  was	  removed	   by	   low	   speed	   centrifugation	   for	   30	  min	   at	   18,460	   x	   g	   and	   4°	   C.	  Supernatant	   was	   carefully	   transferred	   to	   ultracentrifugation	   tubes	   and	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processed	  at	  145,400	  x	  g	  for	  90	  minutes	  at	  4	  °C.	  The	  final	  supernatant	  was	  discarded	   and	   the	   remaining	   membrane	   vesicles	   were	   resuspended	   and	  homogenized	  in	  ice-­‐cold	  25	  mM	  Tris-­‐HCl,	  pH	  8.0	  to	  0.7	  g	  (wet	  weight)/ml,	  corresponding	   to	   about	   30	   mg	   of	   protein/ml.	   Membrane	   vesicles	   were	  frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐80	  °C.	  	  
Protein	  isolation	  and	  purification	  Protein	   isolation	  was	  adapted	   from	  Koçer	  et	  al.	   (73)	  and	  extended	  by	   the	  required	   steps	   for	   StrepTactin-­‐based	   purification.	   Briefly,	   membrane	  vesicles	  corresponding	  to	  about	  60	  mg	  of	  total	  protein	  were	  solubilized	  at	  5	  mg/ml	   in	   a	   solubilization	   buffer	   (50	   mM	   sodium-­‐phosphate	   pH	   8.0,	   300	  mM	  NaCl,	  1	  %	  (v/v)	  Triton	  X-­‐100,	  and	  35	  mM	  imidazole)	  for	  30	  min	  at	  4	  °C.	  Unsolubilized	  material	  was	  removed	  by	  ultracentrifugation	  at	  267,000	  x	  g	  for	   15	   min	   at	   4	   °C.	   Supernatant	   was	   applied	   to	   Ni-­‐NTA	   agarose	   resin	  (Qiagen,	  30	  mg	  membrane	  protein	  per	  ml	  50	  %	  slurry),	  equilibrated	  with	  15	  column	  volumes	  (CV)	  of	  solubilization	  buffer	  and	  incubated	  under	  mild	  agitation	  for	  30	  min	  at	  4	  °C,	  enabling	  binding	  of	  the	  His-­‐tagged	  proteins	  to	  the	  matrix.	  Unbound	  material	  was	  collected	  as	  flow-­‐through	  and	  analyzed	  when	  appropriate.	  The	  column	  was	  washed	  consecutively	  with	  15	  CV	  wash	  buffer	  (50	  mM	  sodium-­‐phosphate,	  pH	  8.0,	  300	  mM	  NaCl,	  0.2	  %	  (v/v)	  Triton	  X-­‐100,	  and	  35	  mM	  imidazole)	  and	  7.5	  CV	  L-­‐histidine	  wash	  buffer	   (50	  mM	  sodium-­‐phosphate	  pH	  8.0,	  300	  mM	  NaCl,	  0.2	  %	  (v/v)	  Triton	  X-­‐100,	  and	  50	  mM	  histidine).	  The	  His-­‐tagged	  proteins	  were	  eluted	  by	  addition	  of	   fifteen	  times	   0.25	   CV	   Ni-­‐NTA	   elution	   buffer	   (50	  mM	   sodium-­‐phosphate,	   pH	   8.0,	  300	  mM	  NaCl,	  0.2	  %	  (v/v)	  Triton	  X-­‐100,	  and	  235	  mM	  L-­‐histidine).	  Protein	  content	  of	  the	  fractions	  was	  checked	  with	  a	  standard	  Bradford	  assay	  (200	  μL	  Bradford	  solution	  and	  10	  μL	  protein	  sample)	  and	  all	  fractions	  containing	  protein	  were	  mixed.	  Subsequently,	  the	  Ni-­‐NTA	  purified	  protein	  was	  applied	  to	  StrepTactin	  resin	  (IBA,	  0.5	  ml	  50	  %	  slurry	  per	  30	  mg	  initial	  membrane	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content),	   equilibrated	   with	   Ni-­‐NTA	   elution	   buffer,	   and	   incubated	   for	   30	  minutes	  (mild	  agitation	  at	  4°	  C)	  to	  allow	  binding	  of	  StrepII-­‐tagged	  proteins.	  The	   remaining	   supernatant	   was	   collected	   as	   flow-­‐through	   and	   the	   resin	  was	  washed	  five-­‐times	  with	  2	  CV	  StrepTactin	  wash	  buffer	  (50	  mM	  sodium-­‐phosphate	  pH	  8,	  300	  mM	  NaCl,	   and	  0.2	  %	   (v/v)	  Triton	  X-­‐100)	   to	   remove	  contaminants.	  The	  bound	  heteropentamers	  were	  eluted	  with	  12	  times	  0.25	  CV	  10	  mM	  biotin	  buffer	  (50	  mM	  sodium-­‐phosphate	  pH	  8.0,	  300	  mM	  NaCl,	  0.2	   %	   (v/v)	   Triton	   X-­‐100,	   and	   10	   mM	   biotin)	   and	   analyzed	   for	   protein	  content	   by	   the	   Bradford	   assay.	   The	   fractions	   with	   the	   highest	   protein	  content	   were	   mixed	   and	   aliquoted.	   Usually,	   the	   total	   yield	   of	  heteropentameric	   protein	   was	   1.5	   -­‐	   2	   mg	   at	   a	   final	   concentration	   of	  approximately	   1	   mg/ml.	   MscL	   heteropentamers	   were	   frozen	   in	   liquid	  nitrogen	  and	  subsequently	  stored	  at	  -­‐80	  °C.	  	  
Heteropentamer	  separation	  by	  chromatofocusing	  Prior	   to	   the	   initial	   chromatofocusing	   experiment,	   the	   isoelectric	   points	  (pIs)	  of	  MscL	  variants	  were	  determined	  using	  a	  sequence-­‐based	  online	  tool	  (http://web.expasy.org/protparam/)	   (43)	   and	   further	   optimized	  empirically.	   For	   that,	   homopentameric	   WT-­‐StrepII	   and	   homopentameric	  G22C-­‐His	   were	   applied	   to	   a	   small	   chromatofocusing	   column	   (Prepacked	  Mono	  P5/50	  GL,	  GE	  Healthcare)	  and	  different	  pH	  gradients	  were	  tested.	  A	  pH	   gradient	   from	   8	   to	   5	   yielded	   optimal	   separation	   of	   both	  homopentamers.	   Heteropentamers	   of	   MscL	   have	   calculated	   pIs	   ranging	  from	  7.3	  (WT4G22C1)	  to	  7.5	  (WT1G22C4),	  whereas	  the	  experimental	  values	  ranged	   from	   ~6.7	   to	   ~7.3.	   This	   window	   of	   pI	   proved	   large	   enough	   to	  resolve	  the	  individual	  complexes	  (Figure	  1	  F).	  	  
	  After	   determining	   the	   pH	   range	   with	   a	   small	   chromatofocusing	   column,	  preparative	   separation	  of	  MscL	  heteropentamers	  were	  performed	  using	  a	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Mono	  P5/200	  GL	  column	  (GE	  Healthcare,	  prepacked	  column),	  which	  allows	  high-­‐resolution	  separation.	  The	  column	  was	  equilibrated	  with	  25	  mM	  Tris-­‐Acetic	   acid	   buffer	   (pH	   8.3).	   After	   a	   pre-­‐gradient	   of	   Polybuffer,	   sample	  mixture	   (1	   ml	   of	   0.6	   mg/ml	   protein)	   was	   injected	   into	   the	   column	   and	  individual	  fractions	  were	  desorbed	  by	  elution	  with	  Polybuffer	  (pH	  5.0)	  at	  a	  flow	  rate	  of	  0.5	  ml/min	  (Figure	  1	  E).	  	  Peak	  fractions	  were	  used	  for	  further	  characterization	  as	  explained	  below.	  	  	  All	  buffers	  and	  solutions	  were	  prepared	  in	  MilliQ	  water	  and	  chilled	  to	  10	  °C.	  The	   pH	   of	   the	   Tris-­‐Acetic	   acid	   buffer	   is	   temperature	   dependent,	   and	  therefore	   the	   pH	   of	   start	   buffer	   and	   eluent	   were	   adjusted	   at	   10	   °C.	  Chromatofocusing	  (CFX)	  purification	  was	  performed	  at	  10	  °C.	  	  (a)	   CFX	   Start	   buffer	   (25	  mM	  Tris-­‐Acetic	   acid	   pH	   8.3,	   10	  mM	  NaCl,	   0.2	  %	  (v/v)	  Triton	  X-­‐	  100)	  (b)	  CFX	  elution	  buffer	  (per	  100	  ml:	  7	  mL	  Polybuffer	  74,	  3	  ml	  Polybuffer	  96,	  10	  mM	  NaCl,	  0.2	  %	  (v/v)	  Triton	  X-­‐100,	  and	  MilliQ	  H2O.	  The	  pH	  was	  set	  to	  5.0	  with	  acetic	  acid)	  (c)	  5	  M	  NaOH	  (d)	  2	  M	  Sodium-­‐acetate	  (e)	  2	  M	  NaCl	  (f)	  MilliQ	  water	  	  All	   solutions	   were	   filtered	   through	   a	   0.2	   μm	  Whatman	   Membrane	   Filter	  (OE66)	  and	  degassed,	  using	  a	  small	  vacuum	  pump.	  	   (1) A	  CFX	  column	  (Mono	  P	  5/200	  GL,	  GE	  Healthcare)	  was	  mounted	  to	  an	  ÄKTA	  purifier.	  (2) A	  two	  ml	  loop	  was	  connected	  for	  probe	  application.	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(3) The	  CFX	  column	  (stored	  in	  20	  %	  EtOH)	  and	  tubing	  and	  pumps	  of	  the	   ÄKTA	   purifier	   were	   washed	   extensively	   with	   filtered	   and	  degassed	  MilliQ	  water.	  (4) Start	  buffer	  and	  eluent	  were	  connected	  to	  the	  system	  and	  pumps	  were	  washed	  with	  10	  ml	  each	  (5) Next,	  two	  ml	  NaOH	  (5	  M)	  were	  injected	  into	  the	  loop	  and	  applied	  to	  the	  column.	  (6) NaOH	  was	  washed	  from	  the	  column	  with	  20	  ml	  start	  buffer.	  (7) Two	   ml	   sodium-­‐acetate	   (2	   M)	   were	   injected	   in	   the	   loop	   and	  applied	  to	  the	  column.	  (8) Sodium-­‐acetate	  was	  washed	   from	   the	   column	  with	   20	  ml	   start	  buffer.	  	  The	  column	  is	  now	  free	  of	  contaminants	  and	  ready	  for	  protein	  purification.	  	  (9) A	  Nap-­‐10	   column	   (GE	  Healthcare)	  was	  equilibrated	  with	  15	  ml	  CFX	  start	  buffer.	  (10) One	  ml	  of	  MscL	  heteropentamers	  (concentration	  1	  mg/ml)	  were	  applied	  to	  the	  column	  and	  allowed	  to	  enter	  the	  matrix;	  the	  flow-­‐through	  was	  discarded.	  (11) 1.5	   ml	   CFX	   start	   buffer	   was	   applied	   to	   the	   column	   and	   one	  fraction	   of	   1.5	   ml	   was	   collected;	   the	   final	   MscL	   concentration	  was	  approximately	  0.6	  mg/ml.	  	  	  After	   buffer	   exchange	   on	   the	   Nap-­‐10	   column,	   the	   sample	   is	   ready	   for	  chromatofocusing.	  The	  MscL	  protein	  could	  be	  frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐80	  °C	  but	  in	  most	  cases	  it	  was	  used	  on	  the	  day	  of	  preparation.	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(12) A	   one	  ml	   loop	  was	   connected	   to	   the	   ÄKTA	   purifier	   for	   sample	  application	  and	  manually	  washed	  with	  CFX	  Start	  buffer.	  (13) The	   desalted	   sample	   of	  MscL	   (>	   1	  ml,	   protein	   concentration	   of	  0.6	  mg/ml)	  was	  carefully	  injected	  into	  the	  loop.	  	  The	   computer-­‐controlled	   program	   for	   CFX	   was	   started.	   This	   program	  controls	   equilibration	   of	   the	   column,	   and	   application	   and	   elution	   of	   the	  protein	  as	  explained	  in	  more	  detail	  below.	  Tracking	  the	  absorbance	  of	  the	  fractions	   at	   254	   nm	   monitored	   the	   protein	   elution	   from	   the	   column.	  Despite	  the	  presence	  of	  Triton	  X-­‐100	  in	  all	  buffers,	  at	  the	  wavelength	  of	  254	  nm	  protein	  specific	  signals	  are	  still	  observed.	  After	  completing	  the	  elution,	  the	   column	   was	   flushed	   with	   water.	   In	   detail,	   the	   chromatofocusing	  program	  is	  a	  series	  of	  five	  consecutive	  blocks:	  	   (14) Block	  1:	  Equilibration.	  The	  column	  was	  equilibrated	  with	  20	  ml	  CFX	  start	  buffer	  at	  a	  flow	  rate	  of	  1	  ml/min.	  (15) Block	  2:	  Pre-­‐gradient.	  A	  pre-­‐gradient	  of	  6	  ml	  CFX	  elution	  buffer	  was	  applied	  to	  the	  column.	  The	  flow-­‐rate	  was	  0.5	  ml/min.	  (16) Block	   3:	   Sample	   injection	   and	   run.	   The	   sample	   (~	   0.6	   mg/ml)	  was	  injected	  and	  elution	  started	  by	  pumping	  CFX	  elution	  buffer	  through	  the	  column	  (0.5	  ml/min).	  After	  five	  times	  1	  ml	  fractions,	  the	  fraction	  volume	  was	  decreased	  to	  0.25	  ml	  to	  allow	  for	  high-­‐resolution	  separation.	   In	   total	  42	  ml	  of	  CFX	  elution	  buffer	  were	  used.	  (17) Start	   buffer	   and	   eluent	   were	   disconnected	   from	   the	   ÄKTA	  purifier	  and	  replaced	  by	  2	  M	  NaCl	  and	  MilliQ	  water	  (18) Block	  4:	   Salt	   strip.	  Remaining	  proteins	  were	   removed	   from	   the	  column	   by	   flushing	   with	   8	   ml	   2M	   NaCl	   at	   a	   flow	   rate	   of	   0.5	  ml/min.	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(19) Block	   5:	   Water	   wash.	   NaCl	   was	   removed	   from	   the	   column	   by	  extensive	  washing	  with	  20	  ml	  MilliQ	  water	  at	  a	   flow-­‐rate	  of	  0.5	  ml/min.	  (20) For	   long-­‐term	   storage,	   the	   column	   was	   transferred	   to	   20	   %	  EtOH.	  	  
Determination	  of	  sample	  pH	  and	  protein	  content	  The	   pH	   value	   of	   individual	   fractions	   was	   determined	   at	   6	   °C	   using	   a	  Sartorius	   pH	   meter	   calibrated	   at	   the	   same	   temperature.	   The	   protein	  content	  of	  the	  peak	  fractions	  was	  determined	  by	  using	  a	  2-­‐D	  Quant	  Kit	  (GE	  Healthcare),	  according	  to	  the	  manufacturers	  protocol.	  Duplicate	  samples	  of	  20	   μL	   were	   assayed,	   using	   BSA	   as	   a	   standard.	   The	   absorbance	   of	   the	  samples	  was	  read	  at	  480	  nm.	  From	  0.6	  mg	  of	  heterooligomeric	  complexes	  (in	  1	  ml	  volume),	  500	  μL	  of	  each	  of	  the	  heterooligomeric	  assemblies	  were	  obtained	   at	   a	   final	   protein	   concentration	   of	   0.15	   mg/ml	   (WT1G22C4	   and	  WT4G22C1)	   and	   0.3	  mg/ml	   (WT2G22C3	   and	  WT3G22C2),	   corresponding	   to	  an	  overall	  recovery	  of	  about	  75	  %	  of	  the	  loaded	  protein.	  	  
Sample	  characterization	  by	  site-­‐directed	  PEGylation	  For	   site-­‐directed	  PEGylation	  purified	  heteropentamers	   of	  MscL	  were	   first	  incubated	   with	   an	   excess	   of	   the	   amino-­‐reactive	   dye	   Cy5-­‐NHS.	   Herefore,	  Cy5-­‐NHS	   solution	   (1mM	   stock	   in	   dry	   DMF)	   was	   added	   to	   the	   protein	  sample	  at	  a	  final	  concentration	  of	  13	  μM	  and	  incubated	  30	  minutes	  at	  4°C	  in	  the	  dark.	  To	  quench	  residual	  free	  dye	  250	  mM	  (final	  concentration)	  lysine	  solution	  was	  added	  and	  the	  mixture	  was	  incubated	  another	  10	  minutes	  at	  4	  °C	  in	  the	  dark.	  Subsequently,	  the	  samples	  were	  incubated	  for	  5	  min	  with	  β-­‐mercaptoethanol-­‐free	   SDS-­‐PAGE	   sample	   buffer.	   Then,	   MTS-­‐PEG5000	  (TRC),	   dissolved	   in	   water	   (10	   mM	   stock),	   was	   added	   to	   a	   final	  concentration	   of	   1.5	   mM	   and	   carefully	   mixed.	   Subsequently,	   the	   protein	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was	  separated	  on	  a	  15	  %	  SDS-­‐PAA	  gel.	  Throughout	  the	  experiment	  the	  gel	  was	   covered	   to	   prevent	   bleaching	   of	   Cy5.	   For	   quantification	   of	   G22C:WT	  ratios,	   the	   gel	   was	   scanned	   using	   a	   Fujifilm	   LAS-­‐3000	   imager	   in	   DIA	  scanning	  mode	  and	  analyzed	  using	  the	  2-­‐D	  quantification	  function	  of	  AIDA	  image	   analyzing	   software	   (raytest	   GmbH).	   For	   calibration	   purposes,	  defined	  amounts	  of	  purified	  G22C	  and	  WT	  MscL	  were	  mixed	  in	  ratios	  of	  4:1,	  3:2,	  2:3,	  1:4	  and	  0:1	  and	  they	  were	  applied	  to	  the	  same	  gel	  as	  the	  sample,	  and	  labeled	  and	  treated	  as	  described	  above.	  	  
Lipid	  preparation	  for	  reconstitution	  Azolectin	  (Soy-­‐Bean,	  Avanti	  polar	  lipids)	  was	  dissolved	  in	  lipid	  buffer	  (150	  mM	   NaCl,	   10	   mM	   sodium-­‐phosphate	   pH	   8.0)	   to	   20	   mg/mL	   by	   30	   s	  sonication	   at	   room	   temperature.	   Subsequently,	   five	   freeze-­‐thaw	   cycles	  were	   performed,	   involving	   rapid	   freezing	   in	   liquid	   N2,	   and	   thawing	   in	   a	  waterbath	  at	  50	  °C.	  Aliquots	  of	  0.5	  ml	  were	  stored	  at	  -­‐80	  °C.	  	  	  
Protein	  reconstitution	  into	  preformed	  liposomes	  Proteins	  were	  reconstituted	  in	  synthetic	  liposomes	  according	  to	  Kocer	  et	  al.	  (73).	  Briefly,	  azolectin	  was	  thawed	  and	  homogenized	  by	  extrusion	  through	  a	   400	   nm	   filter	   (11	   times).	   Liposomes	   were	   destabilized	   by	   addition	   of	  Triton	  X-­‐100.	  Protein	  and	  lipids	  were	  mixed	  at	  1:50	  (weight-­‐to-­‐weight)	  and	  incubated	   for	   30	  minutes	   at	   50	   °C.	   Subsequently,	   buffer	   (10	  mM	   sodium	  phosphate	   pH	   8.0,	   150	   mM	   NaCl)	   was	   added	   in	   1:1	   volume	   ratio	   and	  supplemented	  with	  200	  mg	  (wet	  weight)	  Biobeads	  (SM-­‐2	  Absorbents)	   for	  detergent	  removal.	  The	  sample	  was	   incubated	  overnight	  (~16	  hours)	  at	  4	  oC	  under	  mild	  agitation.	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GUV	  preparation	  by	  electroformation	  Giant-­‐unilamellar	   liposomes	   (GUVs)	   for	   patch	   clamp	   were	   prepared	   as	  explained	   before	   (36).	   Briefly,	   proteoliposomes	  were	   separated	   from	   the	  Biobeads	  by	  a	   short	   centrifugation	   step	   (Eppendorf	  Type	  5418	  centrifuge	  for	  3	  s),	  and	  the	  supernatant	  was	  carefully	  pipetted	  from	  the	  top	  to	  a	  clean	  tube.	  After	  separating	  the	  proteoliposomes	  from	  the	  Biobeads,	  the	  vesicles	  were	  diluted	  to	  a	   final	   lipid	  concentration	  of	  0.8	  mg/mL	  by	  addition	  of	  an	  appropriate	   volume	   of	   MOPS-­‐Tris	   (2mM,	   pH	   7.5).	   After	   dilution,	   2	   µL	  aliquots	   were	   spotted	   onto	   the	   conducting	   site	   of	   an	   ITO	   plate	   (2	   plates	  required)	  and	  dried	  over	  night	  in	  a	  vacuum	  desiccator	  at	  4	  °C.	  GUVs	  were	  prepared	  by	  rehydrating	  the	   lipid	  films	  in	  250	  mM	  sorbitol	  by	  using	   the	   Nanion	   Vesicle	   Prep	   Pro	   instrument.	   The	   electroformation	  protocol	   was	   adapted	   from	   Girard	   et	   al.	   (44)	  with	   an	   AC	   voltage	   applied	  across	  the	  cell	  unit	  for	  3	  hours	  with	  stepwise	  increases	  from	  0.1	  to	  1.1	  V	  at	  12	   kHz	   frequency.	   At	   the	   end,	   in	   order	   to	   detach	   glass	   attached	   giant	  unilamelar	  liposomes,	  the	  AC	  current	  was	  lowered	  to	  4	  Hz	  and	  the	  voltage	  was	   raised	   to	   2V	   for	   30	   min.	   Subsequently,	   GUVs	   in	   sorbitol	   were	  transferred	  to	  a	  clean	  tube	  and	  assayed	  by	  patch	  clamp.	  
	  
Spheroplast	  preparation	  Spheroplasts	   were	   prepared	   as	   described	   before	   (117).	   A	   single	   colony	  derived	  culture	  of	  E.	  coli	  PB104,	  transformed	  with	  the	  appropriate	  plasmid	  (p2BAD	   WT-­‐His	   or	   p2BAD	   WT-­‐StrepII)	   was	   incubated	   overnight	   in	   LB	  medium	   supplemented	   with	   100	   μg/ml	   ampicillin	   and	   10	   μg/ml	  chloramphenicol	   (16	   h,	   37	   °C,	   200	   rpm	  orbital	   shaking).	   The	   culture	  was	  diluted	  1:100	  in	  fresh	  medium	  and	  incubated	  at	  37	  °C	  and	  200	  rpm	  orbital	  shaking	  until	  the	  OD600	  reached	  0.15	  to	  0.2	  (~	  2	  hours).	  Subsequently,	  the	  culture	  was	  diluted	  once	  more	  (10-­‐fold)	  in	  fresh	  LB	  medium	  supplemented	  with	   60	   μg/ml	   Cephalexin.	   After	   two	   hours	   of	   incubation,	   protein	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expression	  was	   induced	  and	  growth	  continued	   for	  30	  minutes.	  Cells	  were	  harvested	  by	  20	  min	  centrifugation	  in	  a	  swing	  out	  rotor	  at	  4000	  x	  g	  and	  4	  °C.	  The	  supernatant	  was	  discarded	  and	  the	  pellet	  was	  gently	  resuspended	  in	  ice-­‐cold	  sucrose	  solution	  (800	  mM).	  Sequentially,	  the	  following	  solutions	  were	  added	  (final	  concentrations	  are	  indicated):	  40	  mM	  Tris-­‐HCl,	  pH	  8,	  200	  μg/ml	  lysozyme,	  50	  μg/ml	  DNase	  and	  6.25	  mM	  EDTA.	  The	  addition	  of	  Tris-­‐HCl,	  lysozyme,	  DNase	  and	  EDTA	  was	  completed	  consecutively	  and	  fast	  (all	  added	  within	  30	  to	  45	  s)	  and	  the	  total	  incubation	  time	  did	  not	  exceed	  5	  min	  at	  RT.	  The	  cell	  wall	  disintegration	  reaction	  was	  terminated	  by	  the	  addition	  of	  ice-­‐cold	  stop	  solution	  (700	  mM	  sucrose,	  20	  mM	  MgCl2,	  10	  mM	  Tris-­‐HCl,	  pH	  8).	  Spheroplast	  were	  harvested	  by	  carefully	  layering	  2	  ml	  sample	  on	  top	  of	  7	  ml	  dilution	  solution	  (800	  mM	  sucrose,	  10	  mM	  MgCl2,	  10	  mM	  Tris-­‐HCl,	  pH	  8)	  in	  clean,	  centrifuge-­‐grade	  glass	  tubes	  and	  subsequent	  centrifugation	  in	   a	   swing-­‐out	   rotor	   at	   4000	   x	   g	   for	   60	   seconds.	   The	   supernatant	   was	  removed	  carefully	  with	  a	  pipette	  until	  only	  the	  pellet	  plus	  ~300	  μl	  solution	  were	   left	   in	   the	   tube.	   After	   resuspension	   of	   the	   pellet,	   the	   sample	   was	  aliquoted	  and	  stored	  at	  -­‐20	  °C.	  
	  
Patch	  clamp	  experiments	  For	   patch-­‐clamp,	   the	   sample	   chamber	   of	   the	   patch	   setup	   was	   filled	   with	  160	  µL	  of	  patch	  buffer	  (200	  mM	  KCl,	  90	  mM	  MgCl2,	  10	  mM	  CaCl2	  plus	  5	  mM	  HEPES-­‐KOH,	   pH	   7.25)	   and	   5	   µL	   GUV	   or	   spheroplast	   sample.	   Pipettes	  (Drummond	   Scientific	   Calibrated	   pipets	   100	   µL)	   with	   1	   μm	   tip	   diameter	  were	  pulled	  using	  Sutter	  Instrument	  P-­‐1000.	  The	  pipette	  tip	  was	  filled	  with	  the	  same	  buffer	  as	  the	  bath.	  All	  recordings	  on	  GUVs	  were	  performed	  with	  excised	  patches	  under	  the	  same	  conditions	  (20	  mV,	  gain	  10,	  sampling	  rate	  of	   30	   µs).	   Spheroplasts	   were	   assayed	   as	   cell	   attached	   patches.	   The	   data	  were	   amplified	   and	   filtered	   at	   10	   kHz	   using	   an	   Axopatch	   1D	   amplifier,	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sampled	   at	   33kHz	   in	   a	   Digidata	   1322A	   digitizer	   and	   analyzed	   with	  pCLAMP10	  software	  (Molecular	  Devices).	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